ARWR Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of 10.7% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of -82.06%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $81.36, signalling upside risk potential of 26.38%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.13 which suggests that it could grow by 10.83%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.213, which suggesting that the stock is 21.339% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $264M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.85x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 8.11x versus 14.00x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 10.7% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of 34.4%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21% beat Eli Lilly & Co.'s return on equity of 104.39%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $81.36, signalling upside risk potential of 26.38%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,202.37 which suggests that it could grow by 17.82%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.213, which suggesting that the stock is 21.339% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $264M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.85x while Eli Lilly & Co.'s PE ratio is 45.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 8.11x versus 14.26x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi has a net margin of 10.7% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of 36.7%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21% beat Sanofi's return on equity of 12.45%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $81.36, signalling upside risk potential of 26.38%. On the other hand Sanofi has an analysts' consensus of $57.68 which suggests that it could grow by 25.01%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Sanofi, analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Sanofi.

Arrowhead Pharmaceuticals, Inc. has a beta of 1.213, which suggesting that the stock is 21.339% more volatile than S&P 500. In comparison Sanofi has a beta of 0.455, suggesting its less volatile than the S&P 500 by 54.501%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi offers a yield of 4.76% to investors and pays a quarterly dividend of $2.20 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sanofi pays out 66.53% of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $264M, which are smaller than Sanofi quarterly revenues of $12.2B. Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M is lower than Sanofi's net income of $4.5B. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.85x while Sanofi's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 8.11x versus 2.28x for Sanofi. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of 10.7% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of -45.06%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $81.36, signalling upside risk potential of 26.38%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 16.62%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Sarepta Therapeutics, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.213, which suggesting that the stock is 21.339% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $264M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.85x while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 8.11x versus 0.79x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.